News

September 23, 2020September 23, 2020

Sumifilam Lowers Levels of Multiple Biomarkers of Disease Activity, Trial Shows

News

Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in people with mild-to-moderate Alzheimer’s after 28 days of treatment, according to final ... Read more

September 21, 2020September 21, 2020

Specific Tau Protein Shows Potential as Blood Biomarker in Early Studies

News

A specific form of the tau protein, called phosphorylated-tau-217 or p-tau217, may function as a blood biomarker of Alzheimer’s disease, allow the development of blood tests to accurately diagnose the disease ... Read more

September 16, 2020September 16, 2020

Theme for World Alzheimer’s Month Is ‘Let’s Talk About Dementia’

News

Events are underway to mark World Alzheimer’s Month, observed every September to raise global awareness about the disease and challenge the stigma regarding dementia. September 21 has been designated World ... Read more

September 14, 2020September 14, 2020

Phase 3 Trial of AXS-05 to Treat Agitation in Alzheimer’s Likely by Year’s End

News

Axsome Therapeutics announced plan to soon open a Phase 3 clinical trial of AXS-05, its investigational oral treatment for Alzheimer’s disease-related agitation, after U.S. Food and Drug Administration (FDA) officials confirmed ... Read more

September 9, 2020September 9, 2020

First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19

News

The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s ... Read more

September 2, 2020September 2, 2020

Part the Cloud Awards $24M to Researchers Studying Potential Alzheimer’s Treatments

News

To help accelerate the development of treatments for Alzheimer’s disease, the Alzheimer’s Association’s Part the Cloud research grant program is investing $24 million in clinical trials investigating 16 potential therapies. ... Read more

August 31, 2020August 31, 2020

Technique That Opens Blood-Brain Barrier May Help Target Treatment, Study Says

News

A new non-invasive technique that can temporarily “open” the blood-brain barrier may make it easier for promising therapies to enter the brain of people with Alzheimer’s disease, a study ... Read more

August 26, 2020August 26, 2020

Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says

News

People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at ... Read more

August 24, 2020August 24, 2020

GAIN Trial Reaches Milestone With 500 Patients Enrolled

News

Cortexyme has reached a milestone after enrolling 500 patients with mild to moderate Alzheimer’s disease in its ongoing Phase 2/3 GAIN clinical trial testing the company’s investigational treatment COR388 ... Read more

August 19, 2020August 19, 2020

AFA Awards $518K for Study of Neuroimmune Interactions in AD Onset, Progression

News

The Alzheimer’s Foundation of America (AFA) has awarded $518,391 in research grant funding to the Broad Institute and One Mind to study the role of the brain’s immune cells ... Read more

Pin It on Pinterest